Acknowledgement
This study was supported by a grant of the Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI), funded by the Ministry of Health and Welfare, Republic of Korea (HF20C0145) and National Research Foundation of Korea (NRF) (NRF-2020R1I1A3072176) funded by the Korean government (Ministry of Science, ICT and Future Planning) and Woosuk University.
References
- Rider TG, Jordan KM. The modern management of gout. Rheumatology (Oxford). 2010;49(1):5-14. https://doi.org/10.1093/rheumatology/kep306
- Dalbeth N, Gosling AL, Gaffo A, Abhishek A. Gout. Lancet. 2021;397(10287):1843-55. https://doi.org/10.1016/S0140-6736(21)00569-9
- Hochberg MC, Thomas J, Thomas DJ, Mead L, Levine DM, Klag MJ. Racial differences in the incidence of gout. The role of hypertension. Arthritis Rheum. 1995;38(5):628-32. https://doi.org/10.1002/art.1780380508
- Choi HK, Mount DB, Reginato AM; American College of Physicians; American Physiological Society. Pathogenesis of gout. Ann Intern Med. 2005;143(7):499-516. https://doi.org/10.7326/0003-4819-143-7-200510040-00009
- Krishnan E, Baker JF, Furst DE, Schumacher HR. Gout and the risk of acute myocardial infarction. Arthritis Rheum. 2006;54(8):2688-96. https://doi.org/10.1002/art.22014
- Dalbeth N, Choi HK, Joosten LAB, Khanna PP, Matsuo H, Perez-Ruiz F, et al. Gout. Nat Rev Dis Primers. 2019;5(1):69.
- Kearney PM, Baigent C, Godwin J, Halls H, Emberson JR, Patrono C. Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials. BMJ. 2006;332(7553):1302-8. https://doi.org/10.1136/bmj.332.7553.1302
- McKenzie BJ, Wechalekar MD, Johnston RV, Schlesinger N, Buchbinder R. Colchicine for acute gout. Cochrane Database Syst Rev. 2021;8(8):CD006190.
- Yook TH. Clinical observation about the extent of improvement of low back pain patient through medi-acupuncture therapy. J Korean Orient Med Soc. 1995;16(1):184-97.
- So AK, Martinon F. Inflammation in gout: mechanisms and therapeutic targets. Nat Rev Rheumatol. 2017;13(11):639-47. https://doi.org/10.1038/nrrheum.2017.155
- Yang G, Yeon SH, Lee HE, Kang HC, Cho YY, Lee HS, et al. Suppression of NLRP3 inflammasome by oral treatment with sulforaphane alleviates acute gouty inflammation. Rheumatology (Oxford). 2018;57(4):727-36. https://doi.org/10.1093/rheumatology/kex499
- Yang G, Lee HE, Moon SJ, Ko KM, Koh JH, Seok JK, et al. Direct binding to NLRP3 pyrin domain as a novel strategy to prevent NLRP3-driven inflammation and gouty arthritis. Arthritis Rheumatol. 2020;72(7):1192-202.
- Rees F, Hui M, Doherty M. Optimizing current treatment of gout. Nat Rev Rheumatol. 2014;10(5):271-83. https://doi.org/10.1038/nrrheum.2014.32
- Richette P, Bardin T. Should prednisolone be first-line therapy for acute gout? Lancet. 2008;372(9646):1301; author reply 1301-2.
- Groff GD, Franck WA, Raddatz DA. Systemic steroid therapy for acute gout: a clinical trial and review of the literature. Semin Arthritis Rheum. 1990;19(6):329-36.
- Lee KH, Cho YY, Kim S, Sun SH. History of research on pharmacopuncture in Korea. J Pharmacopuncture. 2016;19(2):101-8. https://doi.org/10.3831/KPI.2016.19.010
- Bang M, Chang S, Kim JH, Min SY. Pharmacopuncture for asthma: a systematic review and a meta-analysis of randomized controlled trials. Eur J Integr Med. 2017;11:6-17. https://doi.org/10.1016/j.eujim.2017.03.006
- Wang JQ, Li XW, Liu M, Wang SC, Cao ZF. Inhibitory effect of Zanthoxylum bungeanum seed oil on ovalbumin-induced lung inflammation in a murine model of asthma. Mol Med Rep. 2016;13(5):4289-302. https://doi.org/10.3892/mmr.2016.5050
- Kelley N, Jeltema D, Duan Y, He Y. The NLRP3 inflammasome: an overview of mechanisms of activation and regulation. Int J Mol Sci. 2019;20(13):3328.
- Schroder K, Tschopp J. The inflammasomes. Cell. 2010;140(6):821-32. https://doi.org/10.1016/j.cell.2010.01.040
- Martinon F, Glimcher LH. Gout: new insights into an old disease. J Clin Invest. 2006;116(8):2073-5. https://doi.org/10.1172/JCI29404
- Ozenver N, Efferth T. Phytochemical inhibitors of the NLRP3 inflammasome for the treatment of inflammatory diseases. Pharmacol Res. 2021;170:105710.
- Wortmann M, Klotz R, Kalkum E, Dihlmann S, Bockler D, Peters AS. Inflammasome targeted therapy as novel treatment option for aortic aneurysms and dissections: a systematic review of the preclinical evidence. Front Cardiovasc Med. 2022;8:805150.